About us

A Szentágothai János Kutatóközpont a PTE korszerű, nemzetközi tudományszervezési és menedzsment normák szerint kialakított új intézménye, amely az élettudományi, élettelen természettudományi, valamint környezettudományi oktatás...



This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.


Molecular Cardiology Research Group

  • Research concept
  • Members
  • Publications
  • Services
  • Laboratories, instruments
  • Galéria

Despite the advances in the treatment of heart failure over the past decades, this condition represents an enormous public health burden. Considering this unmet clinical need, the elucidation of novel mechanisms involved in heart failure pathogenesis holds the promise of developing new therapies for this prevalent and deadly disease. We focus on protection and regeneration of the diseased heart utilizing multidisciplinary approaches. We envision to translate the findings obtained in preclinical studies (in vitro and ex vivo models, in vivo preclinical small-animal models and clinically relevant large-animal models) toward clinical application or vice versa, from clinical observations back to mechanistic insights. The primary interests of our research group are in the following areas:

Preclinical studies:

  • Identification of novel cardiokine systems regulating cardiac homeostasis (e.g. cardiac function, metabolism, and cell survival) under physiological conditions.
  • Elucidation of cross-talk between cardiac non-myocytes (e.g. fibroblasts) and cardiomyocytes regulating cardiac growth and cell survival during cardiac remodeling.
  • Development of novel small-animal models of heart failure.
  • Establishment of novel large-animal models of heart failure.
  • Establishment of cardiac PET-MRI in large-animal models of heart failure to measure simultaneously left ventricular function, structure, and metabolism (in cooperation with the University of Kaposvár).
  • Proof of concept studies on the beneficial therapeutic effects of intramyocardial delivery of cardiokines in combination with miRNAs and lncRNAs (e.g. impact on cardiac hypertrophy, cell survival, cardiac regeneration, metabolism, angiogenesis, interstitial fibrosis, underlying signaling mechanisms [e.g. epigenetic changes, chromatin remodeling, etc]) in small- and large-animal models of heart failure.

Clinical studies:

  • Identification of novel tissue-specific biomarkers (cardiokines, microRNAs, lncRNAs) for improved prediction of outcome in acute myocardial infarction.
  • Identification of new tissue-specific biomarkers (cardiokines, microRNAs, lncRNAs) to improve risk stratification for cardiac resynchronization therapy in heart failure.

Dr. Attila Cziraki
associate professor
Dr. Iván Horváth
associate professor
+36 72 536001
Prof. Dr. László Lénárd

Zoltán Németh
PhD student

Prof. Dr. Erzsébet Rőth
Doctor of Science

  • Perjes A, Kilpiö T, Ulvila J, Magga J, Alakoski T, Szabo Z, Vainio L, Halmetoja E, Vuolteenaho O, Petäjä-Repo U, Szokodi I, Kerkelä R. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol. 2016;111:29.
  • Nemeth Z, Cziraki A, Szabados S, Biri B, Keki S, Koller A. Elevated levels of asymmetric dimethylarginine (ADMA) in the pericardial fluid of cardiac patients correlate with cardiac hypertrophy. PLoS ONE. 2015;10:e0135498.
  • Perjes A, Skoumal R, Tenhunen O, Konyi A, Simon M, Horvath IG, Kerkela R, Ruskoaho H, Szokodi I. Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms. PLoS ONE. 2014;9:e93473.
  • Lukács E, Magyari B, Tóth L, Petrási Zs, Petneházy Ö, Simor T, Gyöngyösi M, Repa I, Koller Á, Rőth E, Horváth IG. Evaluation of experimental myocardial infarction models via electromechanical mapping and magnetic resonance imaging. Can J Physiol Pharmacol. 2013;91:617-24.
  • Skoumal R, Tóth M, Serpi R, Rysä J, Leskinen H, Ulvila J, Saiho T, Aro J, Ruskoaho H, Szokodi I, Kerkelä R. Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. J Mol Cell Cardiol. 2011;50: 634-41.
  • Kubin AM, Skoumal R, Tavi P, Kónyi A, Perjés Á, Leskinen H, Ruskoaho H, Szokodi I. Role of reactive oxygen species in the regulation of cardiac contractility. J Mol Cell Cardiol. 2011;50:884-93.
  • Development of novel small- and large-animal models of heart failure.
  • Cardiac PET-MRI studies in large-animal models of heart failure (in cooperation with the University of Kaposvár).
  • Testing novel lead compounds in small- and large-animal models of heart failure.
  • Langendorff-type isolated heart perfusion system (MDE Research) for ex vivo evaluation of rat/mouse cardiac function.
  • EPIQ7 Live 3D echocardiograph (Philips) for small- and large-animal models of heart failure.
  • NOGA® system (Biosense Webster, Cordis, Johnson & Johnson) for electromechanical mapping and transendocardial injections in large-animal models of heart failure.
  • Magnetom Avanto 1,5T cardiac MRI (Siemens), and Biograph 3T cardiac PET-MRI (Siemens) for large-animal models of heart failure (in cooperation with the University of Kaposvár).
Dr. István Szokodi
Research Group Leader